Inclusion Criteria:

          -  Patients must have histologically confirmed metastatic or unresectable melanoma

          -  Patients must have a BRAF V600 mutation

          -  Patients must have failed any BRAFi/MEKi regimen to qualify for the trial

          -  Age ≥18 years

          -  ECOG performance status ≤ 1

          -  Patients must have adequate organ and marrow function

          -  Patients with known human immunodeficiency virus (HIV) on effective anti-retroviral
             therapy with undetectable viral load within 6 months are eligible

          -  HBV viral load must be undetectable on suppressive therapy, if indicated.

          -  Patients must have an undetectable HCV viral load.

          -  Patients with treated brain metastases are eligible if follow-up brain imaging 4 weeks
             or longer after central nervous system (CNS)-directed therapy shows no evidence of
             progression.

          -  Patients with a prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial.

          -  Patients with known history or current symptoms of cardiac disease, or history of
             treatment with cardiotoxic agents, should have a clinical risk assessment

          -  women of childbearing potential and men must agree to use adequate contraception

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients with chronic hypokalemia or chronic hypomagnesemia

          -  Patients with long QT syndrome or baseline QTc (Fridericia) >470 msec in males and
             >480 msec in females

          -  Patients who are receiving any other investigational therapies that could affect the
             primary or secondary outcomes of this study

          -  Untreated brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nilotinib, dabrafenib, and trametinib.

          -  Patients receiving any medications or substances that are strong CYP3A or CYP2C8
             inhibitors or substances that are strong CYP3A inducers

          -  Use of Proton pump inhibitors concurrent with nilotinib

          -  Use of drugs or substances known to prolong QT interval is prohibited with Nilotinib

          -  Patients with uncontrolled intercurrent illness.

          -  Patients with psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant or lactating women

          -  Other prior malignancy active within 2 years, except for localized prostate cancer,
             cervical carcinoma in situ, non-melanoma carcinoma of the skin, stage 1 differentiated
             thyroid cancer or ductal carcinoma in situ of the breast that has/have undergone
             curative surgery or radiation